Citations (88)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Dora Grgić, Karlo Golubić, Marko Brinar & Željko Krznarić. (2022) Predictive value of faecal calprotectin in ulcerative colitis – single centre experience. Annals of Medicine 54:1, pages 1570-1577.
Read now
Read now
Johanna Lehtomäki, Anne Nikkonen, Laura Merras-Salmio, Pauliina Hiltunen & Kaija-Leena Kolho. (2022) Therapy outcome related to adalimumab trough levels in pediatric patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology 57:1, pages 31-36.
Read now
Read now
Martin Wollmer, Per Wändell, Mari Rosenqvist, Anders Larsson, Olle Melander, Torgny Wessman, Johan Ärnlöv & Toralph Ruge. (2021) Plasma calprotectin in the emergency department: a potential clinical biomarker for patients with infectious diseases. Scandinavian Journal of Clinical and Laboratory Investigation 81:7, pages 593-597.
Read now
Read now
Kaija-Leena Kolho & Henrik Alfthan. (2020) Concentration of fecal calprotectin in 11,255 children aged 0–18 years. Scandinavian Journal of Gastroenterology 55:9, pages 1024-1027.
Read now
Read now
Pontus Karling, David Lundgren, Vincy Eklöf, Richard Palmqvist & Johan Hultdin. (2019) Improved monitoring of inflammatory activity in patients with ulcerative colitis by combination of faecal tests for haemoglobin and calprotectin. Scandinavian Journal of Clinical and Laboratory Investigation 79:5, pages 341-346.
Read now
Read now
Anja Eberl, Taru Hallinen, Clas-Göran af Björkesten, Markku Heikkinen, Eija Hirsi, Mikko Kellokumpu, Inka Koskinen, Veikko Moilanen, Christian Nielsen, Heikki Nuutinen, Ulla-Maija Suhonen, Karri Utriainen, Ilkka Vihriälä, Erkki Soini, Christina Wennerström, Riikka Nissinen, Andras Borsi, Minni Koivunen, Jyrki Tillonen & Taina Sipponen. (2019) Ustekinumab for Crohn’s disease: a nationwide real-life cohort study from Finland (FINUSTE). Scandinavian Journal of Gastroenterology 54:6, pages 718-725.
Read now
Read now
Anja Eberl, Saara Huoponen, Tapio Pahikkala, Marja Blom, Perttu Arkkila & Taina Sipponen. (2017) Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients. Scandinavian Journal of Gastroenterology 52:12, pages 1348-1353.
Read now
Read now
Lukasz Kwapisz, Jamie Gregor, Nilesh Chande, Brian Yan, Terry Ponich & Mahmoud Mosli. (2017) The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease. Scandinavian Journal of Gastroenterology 52:8, pages 846-850.
Read now
Read now
Marla C. Dubinsky. (2017) Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis. Postgraduate Medicine 129:5, pages 538-553.
Read now
Read now
Kaija-Leena Kolho & Antti Ainamo. (2016) Progress in the treatment and outcome of pediatric inflammatory bowel disease patients. Expert Review of Clinical Immunology 12:12, pages 1337-1345.
Read now
Read now
Erika Lehtola, Johanna Haapamäki & Martti A. Färkkilä. (2016) Outcome of inflammatory bowel disease patients treated with TNF-α inhibitors: two-year follow-up. Scandinavian Journal of Gastroenterology 51:12, pages 1476-1481.
Read now
Read now
Vendel Kristensen & Bjørn Moum. (2015) Correspondence: fecal calprotectin and cut-off levels in inflammatory bowel disease. Scandinavian Journal of Gastroenterology 50:9, pages 1183-1184.
Read now
Read now
Articles from other publishers (76)
Natalia Arroyo-Manzanares, María García-Nicolás, Fuensanta Abellán-Alfocea, Laura Prieto-Baeza, Natalia Campillo, Blanca del Val Oliver, José Zarauz-García, Luis Sáenz & Pilar Viñas. (2023) Application of untargeted volatile profiling in inflammatory bowel disease research. Analytical and Bioanalytical Chemistry 415:17, pages 3571-3579.
Crossref
Crossref
Antonietta Gerarda Gravina, Marcello Dallio, Mario Romeo, Raffaele Pellegrino, Paola Stiuso, Stefania Lama, Paolo Grieco, Francesco Merlino, Iacopo Panarese, Federica Zito Marino, Moris Sangineto, Marco Romano & Alessandro Federico. (2023) The urotensin‐II receptor: A marker for staging and steroid outcome prediction in ulcerative colitis. European Journal of Clinical Investigation 53:6.
Crossref
Crossref
Zuo Wang, Hang Yuan, Xiong Zhu, Jinxia Wang, Wenbo Xiu, Yang Chen, Gao Zhang, Jing Fu, Kun Peng, An Li, Donghua Liu, Xijing Huang, Chong He & Fang Lu. (2023) Fecal calprotectin as an intestinal inflammation marker is elevated in glaucoma. Biomarkers in Medicine 17:9, pages 465-473.
Crossref
Crossref
Sang Hyeon Ahn, Kyu Ha Shin, Jun Taek Oh, Sang Chul Park, Min‐Seok Rha, Soo In Kim, Hyung‐Ju Cho, Joo‐Heon Yoon & Chang‐Hoon Kim. (2023) Calprotectin in chronic rhinosinusitis eosinophil extracellular traps. International Forum of Allergy & Rhinology.
Crossref
Crossref
Sabrina Cenni, Marianna Casertano, Marco Trani, Daniela Pacella, Massimo Martinelli, Annamaria Staiano, Erasmo Miele & Caterina Strisciuglio. (2023) The use of calgranulin-C (S100A12) and fecal zonulin as possible non-invasive markers in children with inflammatory bowel disease: a clinical study. European Journal of Pediatrics 182:3, pages 1299-1308.
Crossref
Crossref
Pauline Veyrard, Xavier Roblin, Céline Pansart, Ren Mao, Stéphane Nancey, Martin Killian, Louis Waeckel, Anne-Emmanuelle Berger, Nicolas Williet, Laetitia Bastide, Mathilde Barrau, Quentin Tournier & Stéphane Paul. (2022) Serum calprotectin is useful to confirm inflammatory bowel disease activity but not to predict relapse. Clinical Immunology Communications 2, pages 33-38.
Crossref
Crossref
Rong-Yue Gao, Hui-Miao Jia, Yu-Zhen Han, Ben-Shu Qian, Pan You, Xiao-Ke Zhang, Wen-Xiong Li & Li-Feng Huang. (2022) Calprotectin as a diagnostic marker for sepsis: A meta-analysis. Frontiers in Cellular and Infection Microbiology 12.
Crossref
Crossref
Guillermo Ramis, Lorena Pérez-Esteruelas, Carolina G. Gómez-Cabrera, Clara de Pascual-Monreal, Belén Gonzalez-Guijarro, Ester Párraga-Ros, Pedro Sánchez-Uribe, Miguel Claver-Mateos, Livia Mendonça-Pascoal & Laura Martínez-Alarcón. (2022) Oral and Parenteral Vaccination against Escherichia coli in Piglets Results in Different Responses. Animals 12:20, pages 2758.
Crossref
Crossref
Lei Liu, Mehdi Sadaghian SadabadGiorgio GabarriniPaola LisottoJulius Z. H. von MartelsHannah R. WardillGerard DijkstraRobert E. SteinertHermie J. M. Harmsen. (2022) Riboflavin Supplementation Promotes Butyrate Production in the Absence of Gross Compositional Changes in the Gut Microbiota. Antioxidants & Redox Signaling.
Crossref
Crossref
Michele MONTORI, Francesco MARTINI, Federico DE BLASIO, Tiziana BUONO, Claudia QUATRACCIONI, Paola GUARDATI, Manuela CALZOLARI, Chiara ROSSI, Emanuele BENDIA, Stefano MENZO, Carmine VALENZA, Rinaldo PELLICANO, Luca MARONI & Antonio BENEDETTI. (2022) Serological response after anti-SARS-CoV-2 BNT162b2 vaccine in IBD patients on biological therapy: a monocentric case-control study. Minerva Gastroenterology.
Crossref
Crossref
Fernando Magro, Diogo Magalhães, Marta Patita, Bruno Arroja, Paula Lago, Isadora Rosa, Helena Tavares de Sousa, Paula Ministro, Irinia Mocanu, Ana Vieira, Joana Castela, Joana Moleiro, Joana Roseira, Eugénia Cancela, Paula Sousa, Francisco Portela, Luís Correia, Mafalda Santiago, Sandra Dias, Catarina Alves, Joana Afonso, Silvio Danese, Laurent Peyrin-Biroulet & Claudia Camila Dias. (2022) Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years. Clinical Gastroenterology and Hepatology 20:9, pages 2059-2073.e7.
Crossref
Crossref
Amira Metwaly, Sandra Reitmeier & Dirk Haller. (2022) Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders. Nature Reviews Gastroenterology & Hepatology 19:6, pages 383-397.
Crossref
Crossref
Gemma Fabozzi, Giulia Verdone, Mariachiara Allori, Danilo Cimadomo, Carla Tatone, Liborio Stuppia, Marica Franzago, Nicolò Ubaldi, Alberto Vaiarelli, Filippo Maria Ubaldi, Laura Rienzi & Gianluca Gennarelli. (2022) Personalized Nutrition in the Management of Female Infertility: New Insights on Chronic Low-Grade Inflammation. Nutrients 14:9, pages 1918.
Crossref
Crossref
Hirotaka Shimizu, Ryo Ebana, Takahiro Kudo, Takuro Sato, Tomoko Hara, Kenji Hosoi, Masaaki Usami, Masashi Yoshida, Ichiro Takeuchi, Hiroshi Nakase, Itaru Iwama, Katsuhiro Arai & Toshiaki Shimizu. (2022) Both fecal calprotectin and fecal immunochemical tests are useful in children with inflammatory bowel disease. Journal of Gastroenterology 57:5, pages 344-356.
Crossref
Crossref
Rebecka Ventin-Holmberg, Miikka Höyhtyä, Schahzad Saqib, Katri Korpela, Anne Nikkonen, Anne Salonen, Willem M. de Vos & Kaija-Leena Kolho. (2022) The gut fungal and bacterial microbiota in pediatric patients with inflammatory bowel disease introduced to treatment with anti-tumor necrosis factor-α. Scientific Reports 12:1.
Crossref
Crossref
Andreas Sturm, Raja Atreya, Dominik Bettenworth, Bernd Bokemeyer, Axel Dignaß, Robert Ehehalt, Christoph Germer, Philip C. Grunert, Ulf Helwig, Klaus Herrlinger, Peter Kienle, Martin E. Kreis, Torsten Kucharzik, Jost Langhorst, Christian Maaser, Johann Ockenga, Claudia Ott, Britta Siegmund, Sebastian Zeißig & Andreas Stallmach. (2022) Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004. Zeitschrift für Gastroenterologie 60:03, pages 332-418.
Crossref
Crossref
Yang Cheng, Tyler R. Hall, Xiao Xu, Ivy Yung, Donald Souza, Jie Zheng, Felix Schiele, Matthias Hoffmann, M. Lamine Mbow, James P. Garnett & Jun Li. (2022) Targeting uPA-uPAR interaction to improve intestinal epithelial barrier integrity in inflammatory bowel disease. eBioMedicine 75, pages 103758.
Crossref
Crossref
Gujjarlapudi Deepika, Namburu Veeraiah, Syed Hassan Naveed & D. Nageshwar Reddy. (2021) Fecal Calprotectin as early predictor for screening and relapse in pediatric chronic diarrhea in India. IP International Journal of Medical Paediatrics and Oncology 7:4, pages 178-184.
Crossref
Crossref
M T Balart, L Russell, N Narula, G Bajaj, U Chauhan, K J Khan, A N Marwaha, E Ching, J Biro, S Halder, F Tse, J K Marshall, S M Collins, P Moayyedi, P Bercik, E F Verdu, G I Leontiadis, D Armstrong & M I Pinto-Sanchez. (2021) Declining Use of Corticosteroids for Crohn’s Disease Has Implications for Study Recruitment: Results of a Pilot Randomized Controlled Trial. Journal of the Canadian Association of Gastroenterology 4:5, pages 214-221.
Crossref
Crossref
Jared Matson, Sonia Ramamoorthy & Nicole E. Lopez. (2021) The Role of Biomarkers in Surgery for Ulcerative Colitis: A Review. Journal of Clinical Medicine 10:15, pages 3362.
Crossref
Crossref
Nidah S Khakoo, Ayanna Lewis, Giovanni A Roldan, Alex Al Khoury, Maria A Quintero, Amar R Deshpande, David H Kerman, Oriana M Damas & Maria T Abreu. (2021) Patient Adherence to Fecal Calprotectin Testing Is Low Compared to Other Commonly Ordered Tests in Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360 3:3.
Crossref
Crossref
Rebecka Ventin-Holmberg, Anja Eberl, Schahzad Saqib, Katri Korpela, Seppo Virtanen, Taina Sipponen, Anne Salonen, Päivi Saavalainen & Eija Nissilä. (2021) Bacterial and Fungal Profiles as Markers of Infliximab Drug Response in Inflammatory Bowel Disease. Journal of Crohn's and Colitis 15:6, pages 1019-1031.
Crossref
Crossref
Mao Matsubayashi, Taku Kobayashi, Shinji Okabayashi, Masaru Nakano, Shintaro Sagami, Ryo Ozaki, Hiroki Kiyohara, Hiromu Morikubo, Kunio Asonuma, Yusuke Miyatani, Shin Maeda & Toshifumi Hibi. (2020) Determining the usefulness of Capsule Scoring of Ulcerative Colitis in predicting relapse of inactive ulcerative colitis. Journal of Gastroenterology and Hepatology 36:4, pages 943-950.
Crossref
Crossref
Carmen Ribes Koninckx, Ester Donat, Marc A. Benninga, Ilse J. Broekaert, Frederic Gottrand, Kaija-Leena Kolho, Paolo Lionetti, Erasmo Miele, Rok Orel, Alexandra Papadopoulou, Corina Pienar, Michela G. Schäppi, Michael Wilschanski & Nikhil Thapar. (2021) The Use of Fecal Calprotectin Testing in Paediatric Disorders: A Position Paper of the European Society for Paediatric Gastroenterology and Nutrition Gastroenterology Committee. Journal of Pediatric Gastroenterology & Nutrition 72:4, pages 617-640.
Crossref
Crossref
Xiaolin Sheng, Dandan Liu, Sujani K. Gamage, Ying Luo, Emilie Viennois, Didier Merlin & Suri S. Iyer. (2021) Point-of-Care Monitoring of Colitis Using Intestinal Alkaline Phosphatase in Inflammatory Bowel Disease. ACS Sensors 6:3, pages 698-702.
Crossref
Crossref
Kohki Okada, Hiroshi Itoh & Masaki Ikemoto. (2021) Serum complement C3 and α2-macroglobulin are potentially useful biomarkers for inflammatory bowel disease patients. Heliyon 7:3, pages e06554.
Crossref
Crossref
Ourania S. Kotsiou, Dimitrios Papagiannis, Rodanthi Papadopoulou & Konstantinos I. Gourgoulianis. (2021) Calprotectin in Lung Diseases. International Journal of Molecular Sciences 22:4, pages 1706.
Crossref
Crossref
Kaija-Leena Kolho. (2021) Therapeutic Drug Monitoring and Outcome of Infliximab Therapy in Pediatric Onset Inflammatory Bowel Disease. Frontiers in Pediatrics 8.
Crossref
Crossref
Andreas Zollner, Andreas Schmiderer, Simon J Reider, Georg Oberhuber, Alexandra Pfister, Bernhard Texler, Christina Watschinger, Robert Koch, Maria Effenberger, Tim Raine, Herbert Tilg & Alexander R Moschen. (2021) Faecal Biomarkers in Inflammatory Bowel Diseases: Calprotectin Versus Lipocalin-2—a Comparative Study. Journal of Crohn's and Colitis 15:1, pages 43-54.
Crossref
Crossref
Dariusz Grzelecki, Piotr Walczak, Marta Szostek, Aleksandra Grajek, Stanisław Rak & Jacek Kowalczewski. (2021) Blood and synovial fluid calprotectin as biomarkers to diagnose chronic hip and knee periprosthetic joint infections. The Bone & Joint Journal 103-B:1, pages 46-55.
Crossref
Crossref
Ana Cardeña Gutiérrez, Xabier Mielgo Rubio, Manuel Ruiz Muñoz, Ruth Martinez Cabañes, Diana Moreno Muñoz, Susana Hernando Polo, Clara Olier Garate, Alicia Hurtado Nuño, Verónica Sotelo Peña, Maria Virginia Sánchez Becerra, Andrea María González López, Mónica Esteban García, Teresa Robles Bermejo, Elia Pérez Fernández & Juan Carlos Cámara Vicario. (2021) Fecal calprotectin as a predictor of gastrointestinal immune-related adverse events (CF-19): A prospective study.. F1000Research 10, pages 534.
Crossref
Crossref
Beatriz Mateos, Esteban Sáez-González, Inés Moret, David Hervás, Marisa Iborra, Elena Cerrillo, Luis Tortosa, Pilar Nos & Belén Beltrán. (2021) Plasma Oncostatin M, TNF-α, IL-7, and IL-13 Network Predicts Crohn’s Disease Response to Infliximab, as Assessed by Calprotectin Log Drop. Digestive Diseases 39:1, pages 1-9.
Crossref
Crossref
Hui Shi, Yu Zuo, Srilakshmi Yalavarthi, Kelsey Gockman, Melanie Zuo, Jacqueline A Madison, Christopher Blair, Wrenn Woodward, Sean P Lezak, Njira L Lugogo, Robert J Woods, Christian Lood, Jason S Knight & Yogendra Kanthi. (2021) Neutrophil calprotectin identifies severe pulmonary disease in COVID-19. Journal of Leukocyte Biology 109:1, pages 67-72.
Crossref
Crossref
Yubo Ma, Dazhi Fan, Shanshan Xu, Jixiang Deng, Xing Gao, Shiyang Guan & Faming Pan. (2020) Calprotectin in spondyloarthritis: A systematic review and meta-analysis. International Immunopharmacology 88, pages 106948.
Crossref
Crossref
Andreas Stallmach, Andreas Sturm, Irina Blumenstein, Ulf Helwig, Sibylle Koletzko, Petra Lynen, Carsten Schmidt, Axel Dignass & Torsten Kucharzik. (2020) Addendum to S3-Guidelines Crohn’s disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic – open questions and answers. Zeitschrift für Gastroenterologie 58:10, pages 982-1002.
Crossref
Crossref
Gulfam Ahmad, Belal Chami, Yuyang Liu, Angie L. Schroder, Patrick T. San Gabriel, Antony Gao, Genevieve Fong, XiaoSuo Wang & Paul K. Witting. (2020) The Synthetic Myeloperoxidase Inhibitor AZD3241 Ameliorates Dextran Sodium Sulfate Stimulated Experimental Colitis. Frontiers in Pharmacology 11.
Crossref
Crossref
Raja Atreya, Markus F. Neurath & Britta Siegmund. (2020) Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?. Frontiers in Medicine 7.
Crossref
Crossref
Beata Polkowska-Pruszyńska, Agnieszka Gerkowicz, Karol Rawicz-Pruszyński & Dorota Krasowska. (2020) The Role of Fecal Calprotectin in Patients with Systemic Sclerosis and Small Intestinal Bacterial Overgrowth (SIBO). Diagnostics 10:8, pages 587.
Crossref
Crossref
Andreas Stallmach, Andreas Sturm, Irina Blumenstein, Ulf Helwig, Sibylle Koletzko, Petra Lynen, Carsten Schmidt, Axel Dignaß & Torsten Kucharzik. (2020) Addendum zu den S3-Leitlinien Morbus Crohn und Colitis ulcerosa: Betreuung von Patienten mit chronisch entzündlichen Darmerkrankungen in der COVID-19-Pandemie – offene Fragen und Antworten. Zeitschrift für Gastroenterologie 58:07, pages 672-692.
Crossref
Crossref
Marine Fauny, Ferdinando D’Amico, Stefanos Bonovas, Patrick Netter, Silvio Danese, Damien Loeuille & Laurent Peyrin-Biroulet. (2020) Faecal Calprotectin for the Diagnosis of Bowel Inflammation in Patients With Rheumatological Diseases: A Systematic Review. Journal of Crohn's and Colitis 14:5, pages 688-693.
Crossref
Crossref
Sung-Hee Han, Joowon Yi, Ji-Hoon Kim & Hee-Won Moon. (2020) Investigation of Intestinal Microbiota and Fecal Calprotectin in Non-Toxigenic and Toxigenic Clostridioides difficile Colonization and Infection. Microorganisms 8:6, pages 882.
Crossref
Crossref
Brigida Barberio, Renata D’Incà, Sonia Facchin, Marianna Dalla Gasperina, Cedric Arsenè Fohom Tagne, Romilda Cardin, Matteo Ghisa, Greta Lorenzon, Carla Marinelli, Edoardo Vincenzo Savarino & Fabiana Zingone. (2020) Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab. Inflammatory Bowel Diseases 26:5, pages 756-763.
Crossref
Crossref
Almuthe Christine Hauer. (2020) Labordiagnostik bei chronisch‑entzündlichen DarmerkrankungenLaboratory diagnostics in chronic inflammatory bowel diseases. Monatsschrift Kinderheilkunde 168:4, pages 314-322.
Crossref
Crossref
Friederike CordesClaudia DemmigArne BokemeyerMarkus BrücknerFrank LenzePhilipp LenzTobias NowackiPhil TepasseHartmut H. SchmidtM. Alexander SchmidtChristoph CichonDominik Bettenworth. (2020) MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease. Clinical and Translational Gastroenterology 11:3, pages e00134.
Crossref
Crossref
Enrique Rodríguez de Santiago, Luis Téllez, Elvira Garrido-Lestache Rodríguez-Monte, Elena Garrido-Gómez, Lara Aguilera-Castro, María Álvarez-Fuente, María Jesús del Cerro & Agustín Albillos. (2020) Fontan protein‐losing enteropathy is associated with advanced liver disease and a proinflammatory intestinal and systemic state. Liver International 40:3, pages 638-645.
Crossref
Crossref
G. V. Lukina, P. I. Kulakova, A. A. Novikov, N. A. Savenkova, E. A. Alexandrova, E. V. Volnukhin & A. N. Kovshik. (2020) Frequency of inflammatory bowel diseases in patients with ankylosing spondylitis. Medical alphabet 2:37, pages 12-15.
Crossref
Crossref
Joowon YiHanah KimHee-Won Moon, Mina HurYeo-Min Yun. (2020)
Clinical Utility of Fecal Neutrophil Gelatinase-Associated Lipocalin and Calprotectin as Biomarkers of
Clostridioides (Clostridium) difficile
Infection
. Laboratory Medicine Online 10:2, pages 125.
Crossref
Crossref
Saara Huoponen, Anja Eberl, Pirjo Räsänen, Risto P. RoineTaina Sipponen, Perttu Arkkila & Marja Blom. (2020) Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease. Medicine 99:2, pages e18723.
Crossref
Crossref
Nobuyuki Takahashi, Chinatsu Kitazawa, Yoshitaka Itani, Yuji Awaga, Aldric Hama, Ikuo Hayashi & Hiroyuki Takamatsu. (2020) Exploratory clinical characterization of experimentally-induced ulcerative colitis nonhuman primates. Heliyon 6:1, pages e03178.
Crossref
Crossref
Michael W. Winter & Joel V. Weinstock. 2020. The Autoimmune Diseases. The Autoimmune Diseases
871
894
.
Salih TOKMAK & Ayşegül HARMANCI ÖZAKYOL. (2019) Elevated Levels of Fecal Calprotectin in Cirrhotic Patients and Spontaneous Bacterial PeritonitisSirotik Hastalarda ve Spontan Bakteriyel Peritonitte Fekal Calprotectin Düzeylerinde Artış. Düzce Tıp Fakültesi Dergisi 21:3, pages 214-217.
Crossref
Crossref
Samuel T. Westreich, Amir Ardeshir, Zeynep Alkan, Mary E. Kable, Ian Korf & Danielle G. Lemay. (2019) Fecal metatranscriptomics of macaques with idiopathic chronic diarrhea reveals altered mucin degradation and fucose utilization. Microbiome 7:1.
Crossref
Crossref
Christopher Andrew Lamb, Nicholas A Kennedy, Tim Raine, Philip Anthony Hendy, Philip J Smith, Jimmy K Limdi, Bu’Hussain Hayee, Miranda C E Lomer, Gareth C Parkes, Christian Selinger, Kevin J Barrett, R Justin Davies, Cathy Bennett, Stuart Gittens, Malcolm G Dunlop, Omar Faiz, Aileen Fraser, Vikki Garrick, Paul D Johnston, Miles Parkes, Jeremy Sanderson, Helen Terry, Daniel R Gaya, Tariq H Iqbal, Stuart A Taylor, Melissa Smith, Matthew Brookes, Richard Hansen & A Barney Hawthorne. (2019) British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 68:Suppl 3, pages s1-s106.
Crossref
Crossref
Emilio J. Laserna-Mendieta & Alfredo J. Lucendo. (2019) Faecal calprotectin in inflammatory bowel diseases: a review focused on meta-analyses and routine usage limitations. Clinical Chemistry and Laboratory Medicine (CCLM) 57:9, pages 1295-1307.
Crossref
Crossref
Fernando Magro, Joanne Lopes, Paula Borralho, Susana Lopes, Rosa Coelho, José Cotter, Francisca Dias de Castro, Helena Tavares de Sousa, Marta Salgado, Patrícia Andrade, Ana Isabel Vieira, Pedro Figueiredo, Paulo Caldeira, A Sousa, Maria A Duarte, Filipa Ávila, João Silva, Joana Moleiro, Sofia Mendes, Sílvia Giestas, Paula Ministro, Paula Sousa, Raquel Gonçalves, Bruno Gonçalves, Ana Oliveira, Isadora Rosa, Marta Rodrigues, Cristina Chagas, Cláudia Camila Dias, Joana Afonso, Karel Geboes & Fátima Carneiro. (2019) Comparison of different histological indexes in the assessment of UC activity and their accuracy regarding endoscopic outcomes and faecal calprotectin levels. Gut 68:4, pages 594-603.
Crossref
Crossref
Yang Woon Lee, Kang-Moon Lee, Ji Min Lee, Yoon Yung Chung, Dae Bum Kim, Yeon Ji Kim, Woo Chul Chung & Chang-Nyol Paik. (2019) The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity. The Korean Journal of Internal Medicine 34:1, pages 72-80.
Crossref
Crossref
Satwik Motaganahalli, Lauren Beswick, Danny Con & Daniel R. van Langenberg. (2019) Faecal calprotectin delivers on convenience, cost reduction and clinical decision‐making in inflammatory bowel disease: a real‐world cohort study. Internal Medicine Journal 49:1, pages 94-100.
Crossref
Crossref
Stephan R Vavricka, Henriette Heinrich, Simon Buetikofer, Flavia Breitenmoser, Emanuel Burri, Xiaoye Schneider-Yin, Jasmin Barman-Aksoezen, Luc Biedermann, Michael Scharl, Jonas Zeitz, Gerhard Rogler, Benjamin Misselwitz & Matthias Sauter. (2018) The Vampire Study: Significant elevation of faecal calprotectin in healthy volunteers after 300 ml blood ingestion mimicking upper gastrointestinal bleeding. United European Gastroenterology Journal 6:7, pages 1007-1014.
Crossref
Crossref
Eleonora Scaioli, Alessandro Sartini, Matteo Bellanova, Massimo Campieri, Davide Festi, Franco Bazzoli & Andrea Belluzzi. (2018) Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology 16:8, pages 1268-1275.e2.
Crossref
Crossref
Joon-Kyung LeeSang-Hyuk JungSang-Eun LeeJoo-Hui HanEunji JoHyun-Soo ParkKyung-Sun HeoDeasun KimJeong-Sook ParkChang-Seon Myung. (2018)
Alleviation of ascorbic acid-induced gastric high acidity by calcium ascorbate
in vitro
and
in vivo
. The Korean Journal of Physiology & Pharmacology 22:1, pages 35.
Crossref
Crossref
Ruth M. Ayling & Klaartje Kok. 2018.
161
190
.
Eleonora Scaioli, Elisa Liverani & Andrea Belluzzi. (2017) The Imbalance between n-6/n-3 Polyunsaturated Fatty Acids and Inflammatory Bowel Disease: A Comprehensive Review and Future Therapeutic Perspectives. International Journal of Molecular Sciences 18:12, pages 2619.
Crossref
Crossref
Peter Bossuyt, Lieven Pouillon, Guillaume Bonnaud, Silvio Danese & Laurent Peyrin-Biroulet. (2017) E-health in inflammatory bowel diseases: More challenges than opportunities?. Digestive and Liver Disease 49:12, pages 1320-1326.
Crossref
Crossref
Alessandro Sartini, Stefano Gitto & Erica Villa. (2017) Does Metabolic Syndrome and Not the Inflammatory Load Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients?. Digestive Diseases and Sciences 62:9, pages 2604-2606.
Crossref
Crossref
Rikke Asmussen Andreasen, Lars Erik Kristensen, Torkell Ellingsen, Robin Christensen, Xenofon Baraliakos, Jimmi Wied, Claus Aalykke, Thomas Ulstrup, Berit Schiøttz-Christensen, Hans Christian Horn, Amir Emamifar, Bent Duerlund, Lars Fischer & Inger Marie Jensen Hansen. (2017) Clinical characteristics of importance to outcome in patients with axial spondyloarthritis: protocol for a prospective descriptive and exploratory cohort study. BMJ Open 7:7, pages e015536.
Crossref
Crossref
Máire A. Conrad & Joel R. Rosh. (2017) Pediatric Inflammatory Bowel Disease. Pediatric Clinics of North America 64:3, pages 577-591.
Crossref
Crossref
Ammar Hassanzadeh Keshteli, Floris F van den Brand, Karen L Madsen, Rupasri Mandal, Rosica Valcheva, Karen I Kroeker, Beomsoo Han, Rhonda C Bell, Janis Cole, Thomas Hoevers, David S Wishart, Richard N Fedorak & Levinus A Dieleman. (2017) Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study. World Journal of Gastroenterology 23:21, pages 3890.
Crossref
Crossref
Saranya Kittanakom, Md. Sharif Shajib, Kristine Garvie, Joceline Turner, Dan Brooks, Sufian Odeh, Robert Issenman, V. Tony Chetty, Joseph Macri & Waliul I. Khan. (2017) Comparison of Fecal Calprotectin Methods for Predicting Relapse of Pediatric Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology 2017, pages 1-10.
Crossref
Crossref
Francesca Palone, Roberta Vitali, Salvatore Cucchiara, Maurizio Mennini, Alessandro Armuzzi, Daniela Pugliese, Renata DʼIncà, Brigida Barberio & Laura Stronati. (2016) Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission. Inflammatory Bowel Diseases 22:12, pages 2886-2893.
Crossref
Crossref
Anastasios Koulaouzidis, Taina Sipponen, Artur Nemeth, Richard Makins, Uri Kopylov, Moshe Nadler, Andry Giannakou, Diana E. Yung, Gabriele Wurm Johansson, Leonidas Bartzis, Henrik Thorlacius, Ernest G. Seidman, Rami Eliakim, John N. Plevris & Ervin Toth. (2016) Association Between Fecal Calprotectin Levels and Small-bowel Inflammation Score in Capsule Endoscopy: A Multicenter Retrospective Study. Digestive Diseases and Sciences 61:7, pages 2033-2040.
Crossref
Crossref
Elisa Liverani. (2016) How to predict clinical relapse in inflammatory bowel disease patients. World Journal of Gastroenterology 22:3, pages 1017.
Crossref
Crossref
Eleonora Scaioli, Michele Scagliarini, Carla Cardamone, Elisa Liverani, Giampaolo Ugolini, Davide Festi, Franco Bazzoli & Andrea Belluzzi. (2015) Clinical application of faecal calprotectin in ulcerative colitis patients. European Journal of Gastroenterology & Hepatology 27:12, pages 1418-1424.
Crossref
Crossref
A. Tursi, A. Papa & S. Danese. (2015) Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon. Alimentary Pharmacology & Therapeutics 42:6, pages 664-684.
Crossref
Crossref
Gerhard Rogler & Luc Biedermann. (2015) Clinical Utility of Biomarkers in IBD. Current Gastroenterology Reports 17:7.
Crossref
Crossref
Kaija-Leena Kolho, Katri Korpela, Tytti Jaakkola, Madharasi V A Pichai, Erwin G Zoetendal, Anne Salonen & Willem M de Vos. (2015) Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation. American Journal of Gastroenterology 110:6, pages 921-930.
Crossref
Crossref
Frank A.J.A. Bodewes, Henkjan J. Verkade, Jan A.J.M. Taminiau, Drucy Borowitz & Michael Wilschanski. (2015) Cystic fibrosis and the role of gastrointestinal outcome measures in the new era of therapeutic CFTR modulation. Journal of Cystic Fibrosis 14:2, pages 169-177.
Crossref
Crossref